• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性膀胱癌患者化疗治疗中的社会人口学差异及其对生存的影响。

Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.

作者信息

Klapheke Amy, Yap Stanley A, Pan Kevin, Cress Rosemary D

机构信息

Public Health Institute, Cancer Registry of Greater California, Sacramento, CA; Department of Public Health Sciences, University of California Davis, Davis, CA.

Department of Urology, University of California Davis, Sacramento, CA; University of California Davis Comprehensive Cancer Center, Sacramento, CA.

出版信息

Urol Oncol. 2018 Jun;36(6):308.e19-308.e25. doi: 10.1016/j.urolonc.2018.03.008. Epub 2018 Apr 5.

DOI:10.1016/j.urolonc.2018.03.008
PMID:29628318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5960436/
Abstract

OBJECTIVE

To evaluate how socioeconomic status and other demographic factors are associated with the receipt of chemotherapy and subsequent survival in patients diagnosed with metastatic bladder cancer.

METHODS

Using data from the California Cancer Registry, we identified 3,667 patients diagnosed with metastatic urothelial carcinoma of the urinary bladder between 1988 and 2014. The characteristics of patients who did and did not receive chemotherapy as part of the first course of treatment were compared using chi-square tests. Logistic regression was used to identify predictors of chemotherapy treatment. Fine and Gray competing-risks regression and Cox proportional hazards regression were used to estimate bladder cancer-specific and all-cause mortality, respectively.

RESULTS

Less than half (46.3%) of patients received chemotherapy. Patients from the lowest socioeconomic quintile were half as likely to have chemotherapy as those from highest quintile (odds ratio = 0.5, 95% CI: 0.4, 0.7). Unmarried patients were significantly less likely to receive treatment (odds ratio = 0.6, 95% CI: 0.5, 0.7). Not receiving chemotherapy was associated with greater mortality from bladder cancer (subdistribution hazard ratio = 1.4, 95% CI: 1.3, 1.5) and from all causes (hazard ratio = 2.0, 95% CI: 1.8, 2.1).

CONCLUSIONS

We found clear disparities in chemotherapy treatment and survival with respect to socioeconomic and marital status. Future studies should explore the possible reasons why patients with low socioeconomic status and who are unmarried are less likely to have chemotherapy.

摘要

目的

评估社会经济地位和其他人口统计学因素与转移性膀胱癌患者接受化疗及后续生存情况之间的关联。

方法

利用加利福尼亚癌症登记处的数据,我们确定了1988年至2014年间被诊断为转移性膀胱尿路上皮癌的3667例患者。使用卡方检验比较了接受和未接受化疗作为第一疗程治疗一部分的患者特征。采用逻辑回归来确定化疗治疗的预测因素。分别使用Fine和Gray竞争风险回归以及Cox比例风险回归来估计膀胱癌特异性死亡率和全因死亡率。

结果

不到一半(46.3%)的患者接受了化疗。社会经济地位最低五分位数的患者接受化疗的可能性仅为最高五分位数患者的一半(优势比 = 0.5,95%置信区间:0.4,0.7)。未婚患者接受治疗的可能性显著较低(优势比 = 0.6,95%置信区间:0.5,0.7)。未接受化疗与膀胱癌更高的死亡率(亚分布风险比 =

相似文献

1
Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.转移性膀胱癌患者化疗治疗中的社会人口学差异及其对生存的影响。
Urol Oncol. 2018 Jun;36(6):308.e19-308.e25. doi: 10.1016/j.urolonc.2018.03.008. Epub 2018 Apr 5.
2
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.化疗、免疫治疗或联合一线治疗转移性膀胱癌:一项大型真实世界经验。
Urol Oncol. 2024 Sep;42(9):291.e13-291.e25. doi: 10.1016/j.urolonc.2024.04.006. Epub 2024 May 19.
3
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?辅助化疗对根治性膀胱切除术治疗肌层浸润性膀胱癌伴不良特征和变异组织学患者的影响:组织学亚型重要吗?
Cancer. 2019 May 1;125(9):1449-1458. doi: 10.1002/cncr.31952. Epub 2019 Jan 8.
4
Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement.膀胱非器官局限性移行细胞癌行根治性膀胱切除术联合或不联合辅助多药化疗:淋巴结受累对预后的影响
Urology. 1996 Dec;48(6):868-75. doi: 10.1016/s0090-4295(96)00299-3.
5
Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions.晚期和转移性膀胱癌患者的全身化疗:现状与未来方向
Ann Oncol. 2005 May;16 Suppl 4:iv85-89. doi: 10.1093/annonc/mdi914.
6
A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.多西他赛每周给药作为转移性尿路上皮癌患者二线化疗的II期研究
Clin Genitourin Cancer. 2016 Feb;14(1):76-81. doi: 10.1016/j.clgc.2015.09.008. Epub 2015 Sep 25.
7
Nordic prospective trials of radical cystectomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer Study Group.北欧根治性膀胱切除术和新辅助化疗的前瞻性试验。北欧膀胱癌症合作研究组。
Eur Urol. 1998;33 Suppl 4:35-8. doi: 10.1159/000052263.
8
Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.吉西他滨-顺铂辅助化疗的疗效:膀胱和上尿路局部晚期移行细胞癌的比较研究
Urol Int. 2010;85(1):47-51. doi: 10.1159/000296294. Epub 2010 Mar 16.
9
The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder.根治性膀胱切除术对转移性膀胱癌患者生存的影响。
J Surg Oncol. 2019 Dec;120(7):1266-1275. doi: 10.1002/jso.25717. Epub 2019 Sep 28.
10
Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder.肌层浸润性膀胱癌新辅助化疗无应答。
Clin Genitourin Cancer. 2014 Jun;12(3):210-3. doi: 10.1016/j.clgc.2013.10.002. Epub 2013 Nov 12.

引用本文的文献

1
The Impact of Socioeconomic Status and Comorbidities on Non-Melanoma Skin Cancer Recurrence After Image-Guided Superficial Radiation Therapy.社会经济地位和合并症对图像引导下浅表放射治疗后非黑色素瘤皮肤癌复发的影响。
Cancers (Basel). 2024 Dec 1;16(23):4037. doi: 10.3390/cancers16234037.
2
Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization.甲羟戊酸途径抑制通过调节 RhoB 蛋白稳定性和整合素 β1 定位减少膀胱癌转移。
Commun Biol. 2024 Nov 9;7(1):1476. doi: 10.1038/s42003-024-07067-8.
3
Existing Health Inequities in the Treatment of Advanced and Metastatic Cancers.晚期和转移性癌症治疗中现存的健康不平等问题。
Curr Oncol Rep. 2024 Dec;26(12):1553-1562. doi: 10.1007/s11912-024-01617-3. Epub 2024 Nov 4.
4
Patient experiences: a qualitative systematic review of chemotherapy adherence.患者体验:化疗依从性的定性系统评价。
BMC Cancer. 2024 May 30;24(1):658. doi: 10.1186/s12885-024-12353-z.
5
N-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges.N6-甲基腺苷修饰的 circ_104797 通过作为 RNA 海绵维持膀胱癌对顺铂的耐药性。
Cell Mol Biol Lett. 2024 Feb 23;29(1):28. doi: 10.1186/s11658-024-00543-3.
6
Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries.美国监测、流行病学和最终结果(SEER)登记处膀胱癌转移性尿路上皮癌患者的区域差异。
Can Urol Assoc J. 2023 Aug 29;17(12):E412-9. doi: 10.5489/cuaj.8442.
7
Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients.化疗对转移性肉瘤样膀胱癌患者总生存期的疗效。
Cent European J Urol. 2022;75(4):352-356. doi: 10.5173/ceju.2022.142. Epub 2022 Nov 25.
8
A model established using marital status and other factors from the Surveillance, Epidemiology, and End Results database for early stage gastric cancer.基于监测、流行病学和最终结果数据库中的婚姻状况和其他因素建立的早期胃癌模型。
J Investig Med. 2022 Aug;70(6):1373-1380. doi: 10.1136/jim-2021-002285. Epub 2022 Jul 5.
9
Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer.膀胱癌淋巴结转移患者生存中的性别二态性。
Ther Adv Med Oncol. 2022 Jun 28;14:17588359221108690. doi: 10.1177/17588359221108690. eCollection 2022.
10
Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators.以医院类型、合并症和治疗延迟为中介因素,对社会经济地位与膀胱癌生存率之间关联的系统评价。
BJUI Compass. 2021 Jan 7;2(3):140-158. doi: 10.1002/bco2.65. eCollection 2021 May.

本文引用的文献

1
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
2
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.2016 年更新版 EAU 肌层浸润性和转移性膀胱癌临床实践指南。
Eur Urol. 2017 Mar;71(3):462-475. doi: 10.1016/j.eururo.2016.06.020. Epub 2016 Jun 30.
3
Urothelial carcinoma management in elderly or unfit patients.老年或身体状况不佳患者的尿路上皮癌管理
EJC Suppl. 2016 Mar;14(1):1-20. doi: 10.1016/j.ejcsup.2016.01.001. Epub 2016 Mar 22.
4
Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.影响经膀胱内卡介苗治疗的高级别非浸润性膀胱癌复发和进展的因素。
Pak J Med Sci. 2014 Mar;30(2):326-30. doi: 10.12669/pjms.302.4117.
5
Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.美国膀胱癌特定分期发病率趋势:1988 年至 2006 年。
Cancer. 2014 Jan 1;120(1):86-95. doi: 10.1002/cncr.28397. Epub 2013 Oct 10.
6
Epidemiology and risk factors of urothelial bladder cancer.尿路上皮膀胱癌的流行病学和危险因素。
Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25.
7
Contemporary management of muscle-invasive bladder cancer.肌层浸润性膀胱癌的当代治疗方法。
Expert Rev Anticancer Ther. 2012 Jul;12(7):941-50. doi: 10.1586/era.12.60.
8
The use and interpretation of competing risks regression models.竞争风险回归模型的使用和解释。
Clin Cancer Res. 2012 Apr 15;18(8):2301-8. doi: 10.1158/1078-0432.CCR-11-2097. Epub 2012 Jan 26.
9
Metastatic bladder cancer: a review of current management.转移性膀胱癌:当前治疗方法综述
ISRN Urol. 2011;2011:545241. doi: 10.5402/2011/545241. Epub 2011 Jun 9.
10
Ethnic differences in bladder cancer survival.膀胱癌生存的种族差异。
Urology. 2011 Sep;78(3):544-9. doi: 10.1016/j.urology.2011.02.042. Epub 2011 Jul 22.